Get started
Author

Katrin Aslan

Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas
2021 · Mirco Friedrich, Roman Sankowski, et al. · Nature Cancer · 248
PDF
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
2020 · Katrin Aslan, Verena Turco, et al. · Nature Communications · 168
PDF
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial
2025 · Martin Wermke, Dejka M. Araujo, et al. · Nature Medicine · 89
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors
2024 · Martin Wermke, Tobias A W Holderried, et al. · Journal for ImmunoTherapy of Cancer · 36
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2023 · Apostolia M. Tsimberidou, Kerstin Guenther, et al. · Cancer Immunology Research · 16
PDF
Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes
2021 · Jens Blobner, Michael Kilian, et al. · Neuro-Oncology Advances · 11
PDF
T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells
2022 · Kevin Hai-Ning Lu, Julius Michel, et al. · Neuro-Oncology Advances · 10
Author Correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial
2025 · Martin Wermke, Dejka M. Araujo, et al. · Nature Medicine · 9
PDF
313 Characterization of PRAME-specific CD4 - CD8 + and CD4 + CD8 + T-cell populations following IMA203CD8 T-cell receptor (TCR) T-cell therapy and their associated helper and cytotoxic functions
2026 · Antonia Busse, Oladapo Yeku, et al. · Journal for ImmunoTherapy of Cancer
Supplementary Figure 11 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
PDF
Supplemental Figure 10 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
PDF
Supplemental Figure 1 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
PDF
Supplemental Figure 4 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
PDF
Supplemental Figure 3 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
PDF
Supplemental Figure 2 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
PDF
Supplemental Figure 6 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
PDF
Supplemental Figure 8 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
PDF
Supplemental Figure 5 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
PDF
Supplemental Figure 9 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
PDF
Supplemental Figure 7 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
PDF
Supplementary Figure 12 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
PDF
Supplementary Figures and Tables from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
579 Quality of starting material result in high manufacturability and favorable product phenotype of IMA203, a PRAME-directed TCR T-cell therapy
2025 · M Alper Kursunel, Brent Chesson, et al. · Journal for ImmunoTherapy of Cancer
PDF
355 An approach to bridging starting materials to monitor T cell persistence in adoptive T cell therapy
2024 · Jourdan Andersson, Olga Dakhova, et al. · Journal for ImmunoTherapy of Cancer
Supplemental Figure 10 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Works count: 89
Citation count: 587
H-index: 8
I10-index: 7
Year
Topic
Type